The results on the first 45 recruited patients showed that palbociclib in combination with tratuzumab is safe and active in HER2-positive breast cancers with advanced disease, pre-treated with trastuzumab, particularly at the level of HER2+/ER+ patients [103]. The gene discussed is ESR1; the disease is breast carcinoma.